

# C-C Chemokine Receptor Type 5 - Pipeline Review, H2 2019

<https://marketpublishers.com/r/C07E9E87C15EEN.html>

Date: November 2019

Pages: 90

Price: US\$ 3,500.00 (Single User License)

ID: C07E9E87C15EEN

## Abstracts

C-C Chemokine Receptor Type 5 - Pipeline Review, H2 2019

### SUMMARY

According to the recently published report 'C-C Chemokine Receptor Type 5 - Pipeline Review, H2 2019'; C-C Chemokine Receptor Type 5 (CHEMR13 or HIV 1 Fusion Coreceptor or CD195 or CCR5) pipeline Target constitutes close to 15 molecules. Out of which approximately 10 molecules are developed by companies and remaining by the universities/institutes.

C-C Chemokine Receptor Type 5 (CHEMR13 or HIV 1 Fusion Coreceptor or CD195 or CCR5) - C-C chemokine receptor type 5 (CCR5) also known as CD195, is a surface protein located on the plasma membrane of white blood cells and is encoded by CCR5 gene. This receptor binds and responds to a variety of chemokines (CCL3, CCL4, CCL5, CCL3L1). This protein is expressed by T cells and macrophages, and is known to be an important co-receptor for macrophage-tropic virus, including HIV, to enter host cells. It plays a role in granulocyte lineage proliferation and differentiation.

The report 'C-C Chemokine Receptor Type 5 - Pipeline Review, H2 2019' outlays comprehensive information on the C-C Chemokine Receptor Type 5 (CHEMR13 or HIV 1 Fusion Coreceptor or CD195 or CCR5) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies/Universities.

It also reviews key players involved in C-C Chemokine Receptor Type 5 (CHEMR13 or

HIV 1 Fusion Coreceptor or CD195 or CCR5) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed and Preclinical stages are 1, 1, 3, 1, 2 and 2 respectively. Similarly, the universities portfolio in Preclinical and Discovery stages comprises 4 and 1 molecules, respectively.

Report covers products from therapy areas Infectious Disease, Oncology, Gastrointestinal, Respiratory, Central Nervous System and Immunology which include indications Human Immunodeficiency Virus (HIV) Infections (AIDS), Metastatic Colorectal Cancer, Non-Alcoholic Steatohepatitis (NASH), Chronic Obstructive Pulmonary Disease (COPD), Liver Fibrosis, Bone Metastasis, Colorectal Cancer, Gastric Cancer, Graft Versus Host Disease (GVHD), Hepatocellular Carcinoma, Liver Cancer, Lung Cancer, Melanoma, Metastatic Pancreatic Cancer, Multiple Sclerosis, Non-Small Cell Lung Cancer, Pancreatic Cancer, Pancreatic Ductal Adenocarcinoma, Primary Sclerosing Cholangitis, Prostate Cancer and Triple-Negative Breast Cancer (TNBC).

**Note:** Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

## SCOPE

The report provides a snapshot of the global therapeutic landscape for C-C Chemokine Receptor Type 5 (CHEMR13 or HIV 1 Fusion Coreceptor or CD195 or CCR5)

The report reviews C-C Chemokine Receptor Type 5 (CHEMR13 or HIV 1 Fusion Coreceptor or CD195 or CCR5) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved in C-C Chemokine Receptor Type 5 (CHEMR13 or HIV 1 Fusion Coreceptor or CD195 or CCR5) targeted therapeutics and enlists all their major and minor projects

The report assesses C-C Chemokine Receptor Type 5 (CHEMR13 or HIV 1 Fusion Coreceptor or CD195 or CCR5) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news and deals related to C-C Chemokine Receptor Type 5 (CHEMR13 or HIV 1 Fusion Coreceptor or CD195 or CCR5) targeted therapeutics

## **REASONS TO BUY**

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand the targeted therapy areas and indications for C-C Chemokine Receptor Type 5 (CHEMR13 or HIV 1 Fusion Coreceptor or CD195 or CCR5)

Identify the use of drugs for target identification and drug repurposing

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding C-C Chemokine Receptor Type 5 (CHEMR13 or HIV 1 Fusion Coreceptor or CD195

or CCR5) development landscape

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

## Contents

Introduction

Global Markets Direct Report Coverage

C-C Chemokine Receptor Type 5 (CHEMR13 or HIV 1 Fusion Coreceptor or CD195 or CCR5) - Overview

C-C Chemokine Receptor Type 5 (CHEMR13 or HIV 1 Fusion Coreceptor or CD195 or CCR5) - Therapeutics Development

Products under Development by Stage of Development

Products under Development by Therapy Area

Products under Development by Indication

Products under Development by Companies

Products under Development by Universities/Institutes

C-C Chemokine Receptor Type 5 (CHEMR13 or HIV 1 Fusion Coreceptor or CD195 or CCR5) - Therapeutics Assessment

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

C-C Chemokine Receptor Type 5 (CHEMR13 or HIV 1 Fusion Coreceptor or CD195 or CCR5) - Companies Involved in Therapeutics Development

Allergan Plc

American Gene Technologies International Inc

Auritec Pharmaceuticals Inc

Bristol-Myers Squibb Co

Cytodyn Inc

Merck & Co Inc

Novartis AG

Orion Biotechnology Canada Ltd

C-C Chemokine Receptor Type 5 (CHEMR13 or HIV 1 Fusion Coreceptor or CD195 or CCR5) - Drug Profiles

(cenicriviroc + tropifexor) - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

(emtricitabine + tenofovir disoproxil fumarate) + maraviroc SR - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

AG-1105 - Drug Profile

Product Description  
Mechanism Of Action  
R&D Progress  
BMS-813160 - Drug Profile  
Product Description  
Mechanism Of Action  
R&D Progress  
cenicriviroc - Drug Profile  
Product Description  
Mechanism Of Action  
R&D Progress  
Drugs to Antagonize CCR5 for Chronic Obstructive Pulmonary Disease - Drug Profile  
Product Description  
Mechanism Of Action  
R&D Progress  
DS-001 - Drug Profile  
Product Description  
Mechanism Of Action  
R&D Progress  
DS-004 - Drug Profile  
Product Description  
Mechanism Of Action  
R&D Progress  
DS-005 - Drug Profile  
Product Description  
Mechanism Of Action  
R&D Progress  
Ierolimab - Drug Profile  
Product Description  
Mechanism Of Action  
R&D Progress  
Monoclonal Antibody to Antagonize CCR5 for Chronic Obstructive Pulmonary Disease (COPD) - Drug Profile  
Product Description  
Mechanism Of Action  
R&D Progress  
OB-002H - Drug Profile  
Product Description  
Mechanism Of Action

R&D Progress

OB-002M - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

OB-002O - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

vicriviroc - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

C-C Chemokine Receptor Type 5 (CHEMR13 or HIV 1 Fusion Coreceptor or CD195 or CCR5) - Dormant Products

C-C Chemokine Receptor Type 5 (CHEMR13 or HIV 1 Fusion Coreceptor or CD195 or CCR5) - Discontinued Products

C-C Chemokine Receptor Type 5 (CHEMR13 or HIV 1 Fusion Coreceptor or CD195 or CCR5) - Product Development Milestones

Featured News & Press Releases

Nov 12, 2019: CytoDyn receives IRB approval to proceed with compassionate use of leronlimab for patients with triple-negative breast cancer

Nov 11, 2019: First patient in CytoDyn's triple-negative metastatic breast cancer trial shows significant reduction in circulating tumor cells (CTC) and reduced tumor size

Nov 06, 2019: American Gene Technologies hosts celebration event for its first IND submission (For HIV) to the Food and Drug Administration (FDA)

Oct 24, 2019: GeoVax Vaccine to be used in a phase 1 trial of genetically modified autologous cell therapy for HIV

Oct 18, 2019: IND application submission to FDA for phase 1 trial Of genetically modified autologous cell therapy for HIV announced by American Gene Technologies

Oct 11, 2019: CytoDyn to present at The MicroCap Rodeo Conference

Oct 03, 2019: CytoDyn to assess leronlimab in Phase II NASH trial

Oct 01, 2019: American Gene Technologies to present at 2019 Cell & Gene Meeting on the Mesa

Sep 27, 2019: CytoDyn treats first patient in phase 1b/2 clinical Trial with Leronlimab (PRO 140) for patients with treatment-Na<sup>+</sup>ve, Metastatic Triple-Negative Breast Cancer

Sep 12, 2019: Orion Biotechnology to initiate clinical trials of its Innovative Microbicide Gel for HIV prevention

Sep 09, 2019: CytoDyn announces FDA clearance to proceed with phase 2 Study of

Leronlimab (PRO 140) and Regorafenib as a combination therapy for metastatic colorectal cancer

Sep 04, 2019: CytoDyn files an IND and a phase 2 protocol with the FDA for the treatment of NASH with Leronlimab

Aug 29, 2019: CytoDyn to present at RHK Capital 2019 Disruptive Growth Conference

Aug 14, 2019: CytoDyn provides update on dose escalating trial with Leronlimab for HIV Monotherapy for a potential pivotal trial

Aug 08, 2019: CytoDyn files a phase 2 protocol with the FDA for Leronlimab (PRO 140) and Regorafenib as a combination therapy for metastatic colorectal cancer

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer



## List Of Tables

### LIST OF TABLES

Number of Products under Development by Stage of Development, H2 2019  
Number of Products under Development by Therapy Areas, H2 2019  
Number of Products under Development by Indications, H2 2019  
Number of Products under Development by Indications, H2 2019 (Contd..1), H2 2019  
Number of Products under Development by Companies, H2 2019  
Products under Development by Companies, H2 2019  
Products under Development by Companies, H2 2019 (Contd..1), H2 2019  
Number of Products under Investigation by Universities/Institutes, H2 2019  
Products under Investigation by Universities/Institutes, H2 2019  
Number of Products by Stage and Mechanism of Actions, H2 2019  
Number of Products by Stage and Route of Administration, H2 2019  
Number of Products by Stage and Molecule Type, H2 2019  
Pipeline by Allergan Plc, H2 2019  
Pipeline by American Gene Technologies International Inc, H2 2019  
Pipeline by Auritec Pharmaceuticals Inc, H2 2019  
Pipeline by Bristol-Myers Squibb Co, H2 2019  
Pipeline by Cytodyn Inc, H2 2019  
Pipeline by Merck & Co Inc, H2 2019  
Pipeline by Novartis AG, H2 2019  
Pipeline by Orion Biotechnology Canada Ltd, H2 2019  
Dormant Products, H2 2019  
Dormant Products, H2 2019 (Contd..1), H2 2019  
Dormant Products, H2 2019 (Contd..2), H2 2019  
Discontinued Products, H2 2019

## List Of Figures

### LIST OF FIGURES

Number of Products under Development by Stage of Development, H2 2019

Number of Products under Development by Therapy Areas, H2 2019

Number of Products under Development by Top 10 Indications, H2 2019

Number of Products by Stage and Mechanism of Actions, H2 2019

Number of Products by Routes of Administration, H2 2019

Number of Products by Stage and Routes of Administration, H2 2019

Number of Products by Molecule Types, H2 2019

Number of Products by Stage and Molecule Types, H2 2019

### COMPANIES MENTIONED

Allergan Plc

American Gene Technologies International Inc

Auritec Pharmaceuticals Inc

Bristol-Myers Squibb Co

Cytodyn Inc

Merck & Co Inc

Novartis AG

Orion Biotechnology Canada Ltd

## I would like to order

Product name: C-C Chemokine Receptor Type 5 - Pipeline Review, H2 2019

Product link: <https://marketpublishers.com/r/C07E9E87C15EEN.html>

Price: US\$ 3,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

[info@marketpublishers.com](mailto:info@marketpublishers.com)

## Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/C07E9E87C15EEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:  
Last name:  
Email:  
Company:  
Address:  
City:  
Zip code:  
Country:  
Tel:  
Fax:  
Your message:

**\*\*All fields are required**

Customer signature \_\_\_\_\_

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970